About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
3,716.0
JPY
+214.0
(+6.11%)
Apr 10, 3:30 pm JST
25.31
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
3,660
Apr 10, 5:48 pm JST
Summary Chart Historical News Financial Result
PER
24.3
PBR
1.20
Yield
4.31%
Margin Trading Ratio
19.70
Stock Price
Apr 10, 2025
Opening Apr 10, 9:06 am
3,712.0 JPY 25.18 USD
Previous Close Apr 9
3,502.0 JPY 24.08 USD
High Apr 10, 9:06 am
3,725.0 JPY 25.31 USD
Low Apr 10, 12:36 pm
3,640.0 JPY 24.78 USD
Volume
2,745,600
Trading Value
0.01T JPY 0.07B USD
VWAP
3686.2 JPY 25.12 USD
Minimum Trading Value
371,600 JPY 2,531 USD
Market Cap
1.08T JPY 7.42B USD
Number of Trades
8,453
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
4,106
1-Year High Jul 29, 2024
17,020
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 61,900 2,597,500 41.96
Mar 28, 2025 49,500 2,528,600 51.08
Mar 21, 2025 59,500 2,521,400 42.38
Mar 14, 2025 67,000 2,555,500 38.14
Mar 7, 2025 77,100 2,526,800 32.77
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.